Home

COURSE DIRECTOR

Giovanni Di Perri

Head of the Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Italy

COURSE SCIENTIFIC SECRETARIAT

Stefano Bonora

Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Italy

Phone + 39 011 4393980/4393867, Fax +39 011 4393882
E-mail stefano.bonora@unito.it

Andrea Calcagno

Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Italy

Phone + 39 011 4393980/4393867, Fax +39 011 4393882
E-mail andrea.calcagno@unito.it

DATES AND SCHEDULE

WEDNESDAY 29 JAN 2024

Residential Pre-Course:


9:30 AM - 1:30 PM

Residential Course and Webinar:


2:30 PM - 5:30 PM

THURSDAY 30 JAN 2024

9:00 AM - 5:30 PM

FRIDAY 31 JAN 2024

9:00 AM - 1:30 PM

COURSE RATIONALE

The course is a remarkable platform for learning, networking, and advancing the understanding of clinical pharmacology in the context of viral, bacterial and fungal infections. It presents a unique opportunity for interdisciplinary cross-fertilization of ideas and incorporation of new approaches in all areas of anti-infective agents, from target identification to clinical application.

Combined as in-person and virtual participation to ensure a wide-reaching and inclusive engagement, the course brings together experts from different fields. Now in its 20th edition, it has progressively expanded to encompass a broad range of topics of clinical pharmacology, thus allowing every participant to exchange the latest scientific knowledge and engage in a comprehensive educational experience.

Not only designed for clinicians who wish to deepen their knowledge about PK/PD aspects of HIV research and medicine, the 3-day course is also a focus on novel issues covering proper use of antibiotics and antifungal agents. Monoclonal antibodies prophylaxis and up-to-date treatment approaches for patients with HIV, RSV and COVID will be also explored. Additionally, pharmacological principles and clinical practical competence in the areas of long-acting anti-infective agents will be widely analyzed and discussed.

LEARNING OBJECTIVES

Upon completion of this course, participants will be better able to:

  • Recognize the role of PK/PD analysis in the development and evaluation of anti-infective agents.
  • Be aware of PK variability of anti-infective drugs and cope with its association with tissue drug penetration and clearance.
  • Optimize strategies for long-term success in the treatment of HIV infection and prevent or minimize DDIs.
  • Describe the new challenges of latest treatments for viral, bacterial and fungal infections and manage treatment optionsfor high-risk or special patient groups.
  • Analyze the use of monoclonal antibodies therapies and explore new strategies for prevention of infectious diseases.
  • Look at real clinical scenarios, reviewing findings and management in the light of PK/PD data and clinical practices guidelines.
  • Provide foundational information on hepatitis delta virus (HDV), addressing gaps in HDV screening and diagnosis and discussing emerging therapeutic options.